Preliminary in vivo studies for the appilcation of Boron Neutron Capture Therapy(BNCT) to the treatment of differentiated and recurrent thyroid carcinoma usingthe histone deacetylase inhibitor, sodium butyrate (NaB) as a radiosentitizer

RODRIGUEZ , C; NIEVAS, S; PERONA, M; BOGGIO, E; LONGHINO, J; CARPANO, M; CABRINI, R; FERNANDEZ, C; JUVENAL, GJ; PISAREV, MA; DAGROSA, MA

Helsinki

Congreso; 16 th Internation Congress on Boron Neutron capture therapy (BNCT).; 2014

Background: NaB in a short chain fatty acid that belongs to a group of compounds described as histone deacetylaces inhibitors (HDACI). Previously we have performed studies using the sodium butyrate (NaB) in combination with boron neutron capture therapy (BNCT) for the treatment of thyroid carcinoma. We demonstrated in vitro that the adition of NaB to the administration of boronophenylalanine (BPA) in the cell culture prior to the irradiation with neutrons produce: decrease of cell survival and increase in the percentage of apoptotic and necrotic cells. Besides, in vivo we observed that when we administrated NaB one day previous to the BPA the tumor, boron uptake selectively increased. The aim of this work was to investigate if NaB besides increasing the boron concentration it also has a radiosensitizer effect in the neutron capture reaction in the tumor. Methods: NIH nude mice (50 individuals) of 6-8 weeks of age were injected subcutaneously in the back right flank with 1,5x106 human follicular thyroid carcinoma (WRO) cells. Twenty days after, tumor bearing animals (tumor size